Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:MBX NASDAQ:ONC NYSEARCA:SCYB NASDAQ:TH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBXMBX Biosciences$12.43-7.2%$11.75$4.81▼$27.50$419.97MN/A263,260 shs339,599 shsONCBeOne Medicines$278.52+3.3%$247.71$148.81▼$287.88$30.53B0.28433,299 shs366,541 shsSCYBSchwab High Yield Bond ETF$26.33+0.2%$26.20$24.73▼$26.79$1.20B0.33445,126 shs668,609 shsTHTarget Hospitality$7.82+0.3%$7.23$4.00▼$11.10$779.48M1.83545,925 shs130,221 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBXMBX Biosciences-3.39%+2.52%+29.22%+78.43%+1,339,999,900.00%ONCBeOne Medicines+6.96%+10.32%+0.03%+18.22%+26,969,999,900.00%SCYBSchwab High Yield Bond ETF-0.27%-0.08%+0.61%+3.06%+1.00%THTarget Hospitality-0.76%+0.91%+13.23%+16.44%-15.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMBXMBX Biosciences1.7086 of 5 stars3.50.00.00.00.61.70.6ONCBeOne Medicines2.4974 of 5 stars3.50.00.00.03.01.70.6SCYBSchwab High Yield Bond ETFN/AN/AN/AN/AN/AN/AN/AN/ATHTarget Hospitality2.9585 of 5 stars3.43.00.00.02.51.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMBXMBX Biosciences 3.00Buy$37.57202.19% UpsideONCBeOne Medicines 3.00Buy$324.8916.65% UpsideSCYBSchwab High Yield Bond ETF 0.00N/AN/AN/ATHTarget Hospitality 2.75Moderate Buy$11.2543.95% UpsideCurrent Analyst Ratings BreakdownLatest MBX, TH, ONC, and SCYB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.007/16/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$311.00 ➝ $349.006/27/2025ONCBeOne MedicinesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$313.00 ➝ $330.006/27/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$317.00 ➝ $321.006/27/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$311.005/8/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$312.00 ➝ $311.005/8/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$348.00 ➝ $350.004/28/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$312.00 ➝ $312.004/24/2025ONCBeOne MedicinesTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$334.00 ➝ $334.004/21/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$311.00 ➝ $317.004/16/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMBXMBX BiosciencesN/AN/AN/AN/AN/AN/AONCBeOne Medicines$3.81B8.01N/AN/A$34.10 per share8.17SCYBSchwab High Yield Bond ETFN/AN/AN/AN/AN/AN/ATHTarget Hospitality$386.27M2.01$1.48 per share5.29$4.26 per share1.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMBXMBX BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/AONCBeOne Medicines-$644.79M-$3.72N/A392.28N/A-9.40%-7.55%-4.42%N/ASCYBSchwab High Yield Bond ETFN/AN/A60.28∞N/AN/AN/AN/AN/ATHTarget Hospitality$71.26M$0.4318.2421.71N/A12.71%11.34%6.94%8/6/2025 (Estimated)Latest MBX, TH, ONC, and SCYB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025THTarget Hospitality-$0.10N/AN/AN/A$56.43 millionN/A5/19/2025Q1 2025THTarget Hospitality-$0.02-$0.05-$0.03-$0.07$65.37 million$69.90 million5/7/2025Q1 2025ONCBeOne Medicines-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMBXMBX BiosciencesN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/ASCYBSchwab High Yield Bond ETF$1.867.07%N/AN/AN/ATHTarget HospitalityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMBXMBX BiosciencesN/AN/AN/AONCBeOne Medicines0.051.961.71SCYBSchwab High Yield Bond ETFN/AN/AN/ATHTarget Hospitality0.101.971.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMBXMBX BiosciencesN/AONCBeOne Medicines48.55%SCYBSchwab High Yield Bond ETFN/ATHTarget Hospitality32.40%Insider OwnershipCompanyInsider OwnershipMBXMBX Biosciences52.19%ONCBeOne Medicines6.62%SCYBSchwab High Yield Bond ETFN/ATHTarget Hospitality68.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMBXMBX Biosciences3633.42 millionN/AN/AONCBeOne Medicines11,000109.60 million102.34 millionN/ASCYBSchwab High Yield Bond ETFN/A45.50 millionN/ANot OptionableTHTarget Hospitality82099.36 million31.80 millionNot OptionableMBX, TH, ONC, and SCYB HeadlinesRecent News About These CompaniesReviewing Target Hospitality (TH) & Its CompetitorsJuly 14 at 4:25 AM | americanbankingnews.comContrasting Target Hospitality (TH) & Its PeersJuly 11, 2025 | americanbankingnews.comTarget Hospitality (TH) vs. Its Competitors Head to Head ReviewJuly 11, 2025 | americanbankingnews.comTeacher Retirement System of Texas Has $2.94 Million Stock Position in Target Hospitality Corp. (NASDAQ:TH)July 9, 2025 | marketbeat.comTarget Hospitality (TH) versus Its Rivals Head-To-Head ComparisonJuly 9, 2025 | americanbankingnews.comWhat's Next: Target Hospitality's Earnings PreviewJuly 8, 2025 | benzinga.comTarget Hospitality Corp. (TH) - Yahoo FinanceJuly 4, 2025 | finance.yahoo.comTarget Hospitality’s Q1 Earnings Call: Our Top 5 Analyst QuestionsJuly 1, 2025 | msn.comTH Target Hospitality Corp. - Seeking AlphaJune 28, 2025 | seekingalpha.comShort Interest in Target Hospitality Corp. (NASDAQ:TH) Expands By 23.9%June 18, 2025 | marketbeat.com50,000 Shares in Target Hospitality Corp. (NASDAQ:TH) Acquired by Fortitude Advisory Group L.L.C.June 17, 2025 | marketbeat.comTH Q1 Earnings Call: Revenue Miss and Government Contract Shifts Shape 2025 OutlookMay 30, 2025 | msn.comAnalysts Offer Insights on Industrial Goods Companies: Target Hospitality (TH), Paccar (PCAR) and Carrier Global (CARR)May 22, 2025 | theglobeandmail.comTarget Hospitality Announces Seat on $4 Billion Multi-Year U.S. Government Strategic Sourcing VehicleMay 21, 2025 | prnewswire.comTarget Hospitality Corp. (NASDAQ:TH) Q1 2025 Earnings Call TranscriptMay 20, 2025 | insidermonkey.comTarget Hospitality Corp. (NASDAQ:TH) Q1 2025 Earnings Call TranscriptMay 20, 2025 | msn.comTarget Hospitality Corp. (TH) Q1 2025 Earnings Call TranscriptMay 19, 2025 | seekingalpha.comTarget Hospitality (NASDAQ:TH) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds ExpectationsMay 19, 2025 | msn.comTarget Hospitality (TH) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 19, 2025 | zacks.comTarget Hospitality (TH) Reports Q1 Loss, Tops Revenue EstimatesMay 19, 2025 | zacks.comTarget Hospitality Reports First Quarter 2025 Results with Continued Focus on Pursuing Strong Strategic Growth PipelineMay 19, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI SpendingMBX, TH, ONC, and SCYB Company DescriptionsMBX Biosciences NYSE:MBX$12.43 -0.97 (-7.22%) As of 03:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.BeOne Medicines NASDAQ:ONC$278.52 +8.82 (+3.27%) As of 03:23 PM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Schwab High Yield Bond ETF NYSEARCA:SCYB$26.32 +0.06 (+0.21%) As of 03:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.The Schwab High Yield Bond ETF (SCYB) is an exchange-traded fund that mostly invests in high yield fixed income. The fund tracks an index of USD-denominated high-yield, US corporate bonds, selected and weighted based on market value. SCYB was launched on Jul 11, 2023 and is managed by Charles Schwab.Target Hospitality NASDAQ:TH$7.82 +0.03 (+0.32%) As of 03:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Target Hospitality Corp. operates as a specialty rental and hospitality services company in North America. The company operates through two segments, Hospitality & Facilities Services - South and Government. It owns a network of specialty rental accommodation units. In addition, the company provides catering and food, maintenance, housekeeping, grounds-keeping, security, health and recreation facilities, workforce community management, concierge, and laundry services. It serves the U.S. government contractors and investment grade natural resource development companies. Target Hospitality Corp. was founded in 1978 and is headquartered in The Woodlands, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
